The NF-κB family of transcription factors is a master regulator of cellular responses during inflammation, and its dysregulation has been linked to chronic inflammatory diseases, such as inflammatory bowel disease. It is therefore of vital importance to design and test new effective NF-κB inhibitors that have the potential to be utilized in clinical practice. In this study, we used a commercial transgenic HeLa cell line as an NF-κB activation reporter to test a novel quinoline molecule, Q3, as a potential inhibitor of the canonical NF-κB pathway. Q3 inhibited NF-κB-induced luciferase in concentrations as low as 5 μM and did not interfere with cell survival or induced cell death. A real-time PCR analysis revealed that Q3 could inhibit the TNF-induced transcription of the luciferase gene, as well as the TNF gene, a known downstream target gene. Immunocytochemistry studies revealed that Q3 moderately interferes with TNF-induced NF-κB nuclear translocation. Moreover, docking and molecular dynamics analyses confirmed that Q3 could potentially modulate transcriptional activity by inhibiting the interaction of NF-κB and DNA. Therefore, Q3 could be potentially developed for further in vivo studies as an NF-κB inhibitor.
The canonical NF-κB pathway is a major regulator of inflammatory responses, and its persistent activation has been linked to chronic inflammatory diseases and cancer development. It is therefore important to develop effective NF-κB inhibitors that can potentially be utilized in further preclinical studies. In this study, we have synthesized various quinazolinone compounds using novel methodologies. We specifically utilized a two-step protocol comparing an established protocol to a modified alternative procedure and then successfully established a novel one-pot multi-component reaction. All quinazolinones were tested based on their capacity to inhibit tumor necrosis factor-induced NF-κB activation using a commercial transgenic HeLa reporter cell-line. Among the eighteen molecules tested, two compounds affected the NF-κB-dependent luciferase activity, the 5o (3-amino-6-hydroxy-2-methylquinazolin-4(3H)-one) and 10 (N-(6-bromo-2-methyl-4-oxoquinazolin-3(4H)-yl)-4-nitrobenzamide). Only the 5o though, bearing OH at R1 (6 position), attenuated the production of pro-inflammatory interleukin 6 in lipopolysaccharide-stimulated human primary macrophage cultures. Molecular docking analysis provides supportive computational evidence that 5o could interact with the p65/DNA complex and therefore could potentially be developed for further studies that aim to inhibit the canonical NF-κB pathway.